Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations. - Wikidata - awgldk - TriplyDB

Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations.

Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations.

http://www.wikidata.org/entity/Q35534719

about

Role of autophagy in COPD skeletal muscle dysfunction Patterns of inflammation and the use of reversibility testing in smokers with airway complaints Systemic inflammation in chronic obstructive pulmonary disease: may adipose tissue play a role? Review of the literature and future perspectives.Cigarette smoking, cadmium exposure, and zinc intake on obstructive lung disorder.A unique protein profile of peripheral neutrophils from COPD patients does not reflect cytokine-induced protein profiles of neutrophils in vitro Chronic obstructive pulmonary disease and the metabolic syndrome: Consequences of a dual threat Proinflammatory cytokines in Egyptian elderly with chronic obstructive pulmonary disease.Respiratory and skeletal muscle strength in chronic obstructive pulmonary disease: impact on exercise capacity and lower extremity function.Chronic obstructive pulmonary disease. 5: systemic effects of COPD The Study of Efficacy, Tolerability and Safety of Theophylline Given Along with Formoterol Plus Budesonide in COPD.Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I.Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis.Extracellular and intracellular decoys in the tuning of inflammatory cytokines and Toll-like receptors: the new entry TIR8/SIGIRR.Therapeutic potential of targeting IL-1 and IL-18 in inflammation.Histone deacetylase activity is decreased in peripheral blood monocytes in patients with COPD.Chronic obstructive pulmonary disease: a novel risk factor for cardiovascular disease.Raised CRP levels mark metabolic and functional impairment in advanced COPD.COPD exacerbations.5: management.Systemic inflammation in COPD in relation to smoking status The challenges of chronic obstructive pulmonary diseases (COPD)--a perspective.Systemic inflammation in COPD: is genetic susceptibility a key factor?Aspects on pathophysiological mechanisms in COPD.Chronic obstructive pulmonary disease: a chronic systemic inflammatory disease.Metabolic syndrome and chronic obstructive pulmonary disease.Skeletal muscle dysfunction in patients with chronic obstructive pulmonary disease.Acute inflammatory and anabolic systemic responses to peak and constant-work-rate exercise bout in hospitalized patients with COPD.Echocardiography, spirometry, and systemic acute-phase inflammatory proteins in smokers with COPD or CHF: an observational study Methods for the assessment of peripheral muscle fatigue and its energy and metabolic determinants in COPD.Mechanisms of striated muscle dysfunction during acute exacerbations of COPD.Pulmonary rehabilitation: the reference therapy for undernourished patients with chronic obstructive pulmonary disease The potential role of endothelial dysfunction and platelet activation in the development of thrombotic risk in COPD patients.Serum levels of IGFBP7 are elevated during acute exacerbation in COPD patients.Surfactant protein D, soluble intercellular adhesion molecule-1 and high-sensitivity C-reactive protein as biomarkers of chronic obstructive pulmonary disease The differences of eosinophil- and neutrophil-related inflammation in elderly allergic and non-allergic chronic obstructive pulmonary disease.Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease.Efficacy of low molecular weight heparin in patients with acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support.Does a history of exercise in COPD patients affect functional status? A study using a lifetime physical activity questionnaire investigates a correlation between exercise and functional status as evidenced by six-minute walk distance.Exhaled nitric oxide, systemic inflammation, and the spirometric response to inhaled fluticasone propionate in severe chronic obstructive pulmonary disease: a prospective study.Impact of aluminum exposure on lung.Lipopolysaccharide binding protein, cytokine production in whole blood, and lipoproteins in cystic fibrosis.

P2860

Q27015002-34F2FF48-E6B9-4E8E-AF85-A1CEA2750CF1 Q33245416-5A92C4DE-8834-4A2A-A942-389FAE44EB3F Q33802207-663CEA3F-EE00-4F75-B315-40F42A1016B6 Q33898390-E7F4B9A2-9ED0-4257-A12C-6AEA8E26BE53 Q34012362-28471D16-E3DF-4E5F-912B-ABCA30C5322B Q34228984-F8B00F4F-D1C6-4E50-A1BF-42709D7EF0BD Q34332855-FD07D273-7723-4353-8609-D1DFB36180F2 Q34903298-13EEFC38-ADC7-44ED-B2F7-5F2472E1B876 Q35009945-5B897A3B-5024-4813-B5CE-5AE3E241D7A8 Q35230530-8B97D4AE-7B60-46D6-BB80-47ADDA553565 Q35536202-D22C8E4A-DB5C-4BCA-9450-F18D1E95F930 Q35536791-D09ECCF7-D37E-4DA1-8B48-C2A54B003A4A Q35606790-456BFF97-AC0A-44A7-95D0-9FF1188DE977 Q35790840-EC0B4F28-EDD7-43AA-9F1A-3C949EDE48C5 Q35984248-3C256E07-C14C-47A7-8A35-30098ED88D14 Q36067003-C2D5804A-40DA-4BC7-BA22-F06960B8D5E0 Q36148662-10727C0E-72F6-408D-87B5-83D7DBCEC774 Q36203144-39493159-B1B3-4740-9DB3-D65BB1A88324 Q36293904-AA26441B-A480-4583-A3CC-C8F45CFAFB6D Q36669465-7168884A-1E6A-42E2-B201-0835BD58BBA7 Q36686862-6DE01ED6-7D67-4C8F-8F2D-205E9423BD27 Q36909567-07EA8805-3B7E-4EB1-8C54-7FCCF4F55C82 Q37016623-FDC45081-81A3-4D55-BE43-86760FD75630 Q37102124-0BE84656-C2A6-499C-AB34-81CFEF087E47 Q37115925-A6E20AF8-7B95-4D92-9C2C-3A2C2FE5B3B1 Q37236567-E09B703F-2F77-4A84-A482-C51A1D6F9339 Q37297427-906FA9C7-0EBF-4F47-AFD0-FE45A7BB4EC2 Q37655139-546C5466-5974-415D-98A5-09CDCB56720F Q38078336-C29464BE-BFEC-44D6-8E70-C14F64A634DA Q39216001-090F8541-3D25-4A76-89E0-B5D40702F037 Q39426025-B562B34A-246E-4D6A-A297-4806752094AA Q41034825-E4E70F38-3CAD-4461-B185-6494F9E1B00B Q42759714-A5045C9C-3D04-4E6E-8DF2-9F50C37D9DC4 Q42880991-139E38A9-C5D2-468E-AB15-672B093C68C5 Q44960162-305CC120-16F5-4820-8696-3A57A360BB51 Q45156975-63891C54-86EF-449C-A73E-B8722FA3D47D Q46136283-E40FE64E-388B-4C24-9537-C3EE5352A117 Q46174569-D1355E5C-5121-4481-8B4D-BCAC97A25C39 Q46606639-81B86E70-F3BB-47D5-AE20-8E10187729FA Q46720517-8C380F38-221E-4F56-9EF8-1B80DA52E2B3

P2860

Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations.

http://www.wikidata.org/entity/Q35534719

description

2001 nî lūn-bûn

@nan

2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Systemic anti-inflammatory med ...... ng treatment of exacerbations.

@ast

Systemic anti-inflammatory med ...... ng treatment of exacerbations.

@en

type

label

Systemic anti-inflammatory med ...... ng treatment of exacerbations.

@ast

Systemic anti-inflammatory med ...... ng treatment of exacerbations.

@en

prefLabel

Systemic anti-inflammatory med ...... ng treatment of exacerbations.

@ast

Systemic anti-inflammatory med ...... ng treatment of exacerbations.

@en

P1433

Q35534719-62BE6453-9FCB-49E9-B002-C2653A488DC4

P1476

Q35534719-2F9AB732-4F27-447A-A70E-DF2106AD7976

P2093

Q35534719-322533E7-01D6-48B3-BFE6-08B7D8F20F96

Q35534719-5FF8A7C1-DDF7-4958-BDC0-07A351BACC6B

Q35534719-77A6C52D-33D7-41B4-A1BA-C16D85501160

Q35534719-8014A80B-E173-44A2-9AD5-4242CBDC003C

Q35534719-AFF34D72-CB73-420A-BFBF-F6096958299A

Q35534719-B9B93746-CD53-4881-A805-FEFBCD28737A

P2860

Q35534719-02497F92-6462-41FE-9FF2-236F96A66241

Q35534719-0A0B1C72-DFE8-43F2-B071-210354CADA2A

Q35534719-12B73DA9-543F-410F-8ED0-F4D46FCFB3B1

Q35534719-24503726-B5A6-476B-8E3B-A8CCD1CF3C04

Q35534719-299EEF35-5F73-4D0B-BD51-779959BDA422

Q35534719-36832EAF-FF19-4762-B3D7-DC2A2C401573

Q35534719-4B8D17F0-502D-4412-A309-123E35801312

Q35534719-4DF19EDB-11C3-47D5-BF39-745D38BA36A0

Q35534719-5D9752B5-0B81-4A6D-88F5-2490C54695AB

Q35534719-837BEB7F-E9B6-4BA2-8AD3-FC691F8F7E47

P304

Q35534719-8B5DD268-ADC7-4671-9DA3-011D4F277B9F

P31

Q35534719-AD13C740-3744-403C-A0C2-BE8AA9CD3B71

P356

Q35534719-6B4CFE2E-672E-4ABB-9AEF-1D15C71F89DD

P407

Q35534719-240A76C1-3107-4FCA-B353-5BC56CE41519

P433

Q35534719-CB83B5D0-F023-49C9-BD41-8C7EEAD7B703

P478

Q35534719-C66CD414-EFFA-4491-AFCA-01F5C820DBA0

P50

Q35534719-0F76276D-F045-4FB4-A5F2-15DF9F316E53

P577

Q35534719-A40420BE-1C3F-4C9B-93B3-018600AA1689

P5875

Q35534719-4B33AC87-E0AD-43EE-95AC-4D993CAED4F5

P698

Q35534719-93AE023A-DF79-4C9D-B8F8-45507AD51D3E

P921

Q35534719-A805F281-2777-4DB9-8A3F-7DC6FF4CC9E1

P932

Q35534719-C5EDC638-87A5-4937-9FCE-192F90C8EAA6

P356

THORAX.56.9.721

P1433

P1476

Systemic anti-inflammatory med ...... ng treatment of exacerbations.

@en

P2093

Buurman WA

http://www.w3.org/2001/XMLSchema#string

Creutzberg EC

http://www.w3.org/2001/XMLSchema#string

Dentener MA

http://www.w3.org/2001/XMLSchema#string

Schols AM

http://www.w3.org/2001/XMLSchema#string

Wouters EF

http://www.w3.org/2001/XMLSchema#string

van't Veer C

http://www.w3.org/2001/XMLSchema#string

P2860

A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types

Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4

Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society

A comparison of the reproducibility and the sensitivity to change of visual analogue scales, Borg scales, and Likert scales in normal subjects during submaximal exercise.

Factors influencing airway inflammation in chronic obstructive pulmonary disease.

Binding of IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids.

Elevated levels of shed type II IL-1 receptor in sepsis. Potential role for type II receptor in regulation of IL-1 responses.

Regulated expression and release of the IL-1 decoy receptor in human mononuclear phagocytes.

Statistical guidelines for contributors to medical journals.

Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations.

P304

721-726

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/THORAX.56.9.721

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

56

http://www.w3.org/2001/XMLSchema#string

P50

Alberto Mantovani

P577

2001-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

277457741

http://www.w3.org/2001/XMLSchema#string

P698

11514694

http://www.w3.org/2001/XMLSchema#string

P921

P932

1746133

http://www.w3.org/2001/XMLSchema#string